Relypsa Monthly Prescriptions Jump
Relypsa Inc (NASDAQ:RLYP) shares are around 4% higher after the company reported the number of retail prescriptions for Veltassa rose by 32.5% sequentially to 1,230. Veltassa is Relypsa’s main product and represents a treatment for hyperkalemia. Some traders expect demand for the drug to grow considerably over the next year given that the FDA didn’t approve ZS-9, a competitor’s hyperkalemia drug candidate. A total of 14 investors tracked by us were long Relypsa Inc (NASDAQ:RLYP) at the end of March, down by 7 from the previous quarter.
Offering at Tonix
Nanocap Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is 20% in the red in pre-market after the company announced its intention to offer shares of common stock in an underwritten public offering. Although the pricing of the offering hasn’t been released, Tonix has said it plans to use the net proceeds to finance the development of cyclobenzaprine HCl sublingual tablets for the management of fibromyalgia, advance the development of TNX-102 SL for the potential treatment of post traumatic stress disorder, and for general corporate purposes. Among the funds we follow, Mark Kingdon’s Kingdon Capital owned over 1.5 million shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) at the end of March.
FireEye Buzzing on Bloomberg Article
FireEye Inc (NASDAQ:FEYE) shares are in the green this morning after Bloomberg published an article stating that FireEye had rebuffed several takeover proposals made by multiple parties earlier this year. FireEye’s management turned down the proposals because the offers were below the company’s expectations of $30 per share or more. One of the potential suitors of FireEye was Symantec Corporation (NASDAQ:SYMC), which recently bought Blue Coat Systems instead. FireEye is said to no longer be looking to sell itself anymore. A total of 28 funds in our database were long FireEye Inc (NASDAQ:FEYE) at the end of the first quarter, up by three funds from the previous quarter.